Pipeline Category: ANB033

CD122 Antagonism Prevented Inflammation in a Murine Model of Celiac Disease and Inhibited the Activity of Cytotoxic CD8+ and Activated CD4+ T Cells from Celiac Patients In Vitro

October 19, 2026

CD122 Antagonism Prevented Lung and Esophageal Inflammation in a Murine Model of Eosinophilia and Reduced T cell Activity in Human Cells In Vitro

October 15, 2026

ANB033, a Novel CD122 Antagonist in Development for the Treatment of Inflammatory and Autoimmune Diseases, Inhibited IL-15 and IL-2 Signaling in CD8+ and CD4+ T Cells In Vitro and in a Murine Model of GvHD

June 9, 2026

Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases

July 19, 2023